Analyst Coverage Resumed: AUPH rating Overweight by Cantor Fitzgerald
Price Target: $34>>25
Report Date: 05-05-2022
Symbol: AUPH - Aurinia Pharmaceuticals Inc.
Sector: Healthcare
Industry: Biotechnology
Analyst Coverage Resumed: AUPH rating Overweight by Cantor Fitzgerald
Price Target: $34>>25
Aurinia Pharmaceuticals Inc. (AUPH)
1203-4464 Markham St
Victoria, BRITISH COLUMBIA V8Z 7X8
Phone: 12507084272
Website: http://www.auriniapharma.com
CEO: Mr. Peter Greenleaf
NASDAQ, Nasdaq Global Market
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.
free stock signals, free stock market signals, free stock signal software, stock trading signals
Good stock signals have been found on this server. That is all we know.
+1 (407) 559-7228